Iqbal S. Grewal

Iqbal Singh Grewal, PhD, DSc, FRCPath: Biopharma executive with 30+ years of immunotherapy R&D experience spanning biotech, big pharma, and top academic institutions, including 20+ years of experience in C-level, Company Board, Global Head, and VP-level roles. Entrepreneur and company founder, deeply involved in the inception, fundraising, and, and early-stage advising of multiple successful biotechnology companies. World-leading industry expert in novel biotherapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), bispecific molecules, antibody-cytokine conjugates, fusion proteins, checkpoint inhibitors, immune agonists, CAR-T cells, iPSC-derived allogeneic cell therapies, T cell redirectors, vaccines, TME modulators, myeloid cell targeting and other immune-oncology evolving technologies Established oncology & immunology drug developer, having led the discovery and development of >60 molecules, many of which have progressed into human clinical trials & include approved drugs. Accomplished immunologist and thought leader within cancer immunology & autoimmunity, having published over 120 papers (including in Nature, Science, Immunity, Nature Immunology, Nature Medicine, PNAS, JEM, etc.) and edited two books on biologic therapeutics. Frequently sought to contribute reviews/opinions & serve as Senior Editor. Seasoned division leader, having built & led teams across the entire spectrum of drug development, including discovery, IND filing, patent filing, safety/toxicology, PK/PD, regulatory, biomarkers, and Ph. I clinical trials. Extensive experience in chairing high-level committees and cultivating interactions with academia, industry, advisors, KOLs, SAB, board members, and executive committees. Highly-solicited thought leader across immunotherapy in the areas of costimulation, TNF superfamily, immuno-oncology, tolerance, and cellular therapeutics. Served in advisory roles, including SABs (Immusoft, Meditope, ImmunoBioChem, Antibody Society, Pear Bio), Company Board (ImmunGene), Journal Editorial Boards, and as Ad Hoc advisor (e.g. patent litigation). Prolific inventor, having discovered many novel molecules & technologies resulting in over 200 worldwide applications and issued patents. Specially recognized for outstanding contributions to medical research and drug development, including through election as Fellow by both the Royal College of Pathologists and the Royal Microscopical Society, as well as awarding of a Doctor of Science (DSc) degree in medical research by the University of Aberdeen, UK.